Menu
Back to Journals » Clinical Ophthalmology » Volume 5
Treating ocular surface disease: new agents in development
Published 14 April 2011 Volume 2011:5 Pages 465—472
DOI https://doi.org/10.2147/OPTH.S12291
Review by Single anonymous peer review
Peer reviewer comments 3
Ahmad M Fahmy, David R Hardten
University of Minnesota, Minneapolis, MN, USA
Abstract: This paper reviews recent advances and investigation in the treatment of ocular surface pathology. There is significant investment in this area, paralleling the growing demand for more effective alternatives to current treatments. Clinicians are becoming more aware of surface pathology, yet the ability to treat the most common forms of ocular pathology are still limited to the few medications approved by the US Food and Drug Administration. Medicines and devices currently under investigation are very promising. It is absolutely critical to understand the emerging options and think of their role in the treatment paradigm.
Keywords: dysfunctional tear syndrome, anti-inflammatory drugs, treatment
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.